- Forbes•21 hours ago
Now that AstraZeneca’s transition to the cloud is largely in place, it is seeing broad business benefits across the organization. Cloud-based solutions enabled AstraZeneca to implement work faster than legacy tools would have allowed. The company is also taking advantage of the efficiency of the cloud model, including a reduction in capital expenditure, the ability to scale up and down, and the fact that it needs fewer people to support apps like Workday or ServiceNow as compared to SAP.
- Zacks•2 days ago
AstraZeneca plc (AZN) announced that the FDA has accepted for review its complete re-submission of the new drug application (NDA) for ZS-9 (sodium zirconium cyclosilicate).
AstraZeneca PLC (AZN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||30.91 x 1300|
|Ask||30.93 x 2900|
|Day's Range||30.76 - 31.14|
|52wk Range||26.97 - 35.04|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||35.43|
|Avg Vol (3m)||5,558,600|
|Dividend & Yield||0.90 (2.93%)|